The generic name for Ingrezza is valbenazine [1].
What is valbenazine used for?
Valbenazine is a medication prescribed to treat tardive dyskinesia, a side effect of certain antipsychotic medications that causes involuntary, repetitive movements [1].
When will Ingrezza (valbenazine) lose its patent exclusivity?
The primary patents protecting Ingrezza are set to expire in [Insert relevant patent expiry year, if available in provided text]. Patent challenges and additional patent filings can affect the exact timeline for generic market entry [2]. You can find more detailed patent information on DrugPatentWatch.com [2].
How does valbenazine work?
Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. By inhibiting VMAT2, it reduces the uptake of monoamines into synaptic vesicles, which is believed to modulate dopamine signaling in the brain, thereby improving symptoms of tardive dyskinesia [1].
Are there other treatments for tardive dyskinesia?
Besides valbenazine, other VMAT2 inhibitors approved for tardive dyskinesia include deutetrabenazine. Other management strategies may involve adjusting the dosage or type of antipsychotic medication, although this is not always feasible [3].
What are the potential side effects of valbenazine?
Common side effects reported for valbenazine include somnolence (drowsiness), dry mouth, and constipation. More serious, though less common, side effects can include an increased risk of suicidal thoughts and behaviors, as well as somnolence that may impair a patient's ability to drive or operate machinery [1].
Can I get valbenazine cheaper as a generic?
Once generic versions of valbenazine become available after patent expiry, they are typically offered at a lower price than the brand-name Ingrezza [4]. The availability and pricing of generics depend on regulatory approval and market competition [4].
Where can I find more information about Ingrezza patents?
DrugPatentWatch.com provides comprehensive patent information for Ingrezza, including patent expiry dates and any ongoing legal challenges [2].
What are the clinical trial results for valbenazine?
Clinical trials have demonstrated that valbenazine can significantly reduce abnormal involuntary movement scale (AIMS) scores in patients with tardive dyskinesia. Studies have shown a statistically significant improvement in AIMS scores compared to placebo in patients treated with valbenazine [1].
What is the mechanism of action of VMAT2 inhibitors?
VMAT2 inhibitors like valbenazine work by targeting the vesicular monoamine transporter 2. This transporter is responsible for packaging monoamine neurotransmitters, such as dopamine, into vesicles for release. By inhibiting VMAT2, these drugs reduce the amount of dopamine available in the synaptic cleft, which is thought to alleviate the motor control issues associated with tardive dyskinesia [1].
Sources:
1. [Insert source for valbenazine information, e.g., FDA label, clinical trial summary]
2. [Insert link to DrugPatentWatch.com if mentioned in provided text]
3. [Insert source for other tardive dyskinesia treatments, e.g., clinical guidelines]
4. [Insert source discussing generic drug pricing, if available in provided text]